Want to see BGMS full AI Analyst Report?
Top Page
Bio Green Med Solution
(NASDAQ:BGMS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.89
▼(-3.15% Downside)
Action:Reiterated
Date:08/20/26
The score is held down primarily by weak profitability and ongoing cash burn despite improving revenue and a low-debt balance sheet. Technical signals are broadly neutral, while corporate events add both positives (improved results and strategic refocus) and major dilution risk tied to recent financing and the announced acquisition structure.
Positive Factors
Revenue Growth
Improving revenue indicates stronger commercialization and customer adoption. Continued growth would provide a larger base for operating leverage, particularly as the company focuses on fire safety and related environmental services.
Negative Factors
Severe Unprofitability
Very low gross profitability and operating losses exceeding revenue show that BGMS has not yet established a scalable cost structure. Sustained losses could limit reinvestment capacity and require additional financing before growth translates into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Improving revenue indicates stronger commercialization and customer adoption. Continued growth would provide a larger base for operating leverage, particularly as the company focuses on fire safety and related environmental services.
Read all positive factors
Bio Green Med Solution (BGMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.00M
Dividend YieldN/A
Average Volume (3M)473.94K
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth18510.00%
EPS Growth98.80%
CountryUS
Employees12
SectorIndustrials
Sector Strength72
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-3.64
Shares Outstanding6,622,794
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bio Green Med Solution Business Overview & Revenue Model
Company Description
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fit...
Bio Green Med Solution Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.Positive Updates
Progress in Fadra Phase II Study
Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.
Negative Updates
Decrease in R&D Tax Credits
UK research and development tax credits decreased significantly to $0.4 million for Q2 2024, compared to $6 million for the same period in the previous year.
Read all updates
Q2-2024 Updates
Positive
Negative
Progress in Fadra Phase II Study
Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.
Read all positive updates
Company Guidance
During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.Bio Green Med Solution Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86M | 747.00K | 43.00K | 420.00K | 0.00 | 0.00 |
| Gross Profit | 360.00K | 138.00K | 43.00K | 420.00K | -32.00K | -43.00K |
| EBITDA | -2.73M | -8.42M | -12.00M | -25.42M | -27.62M | -22.35M |
| Net Income | -2.20M | -3.00M | -11.21M | -22.55M | -21.20M | -18.46M |
Balance Sheet | ||||||
| Total Assets | 7.85M | 8.19M | 4.09M | 8.80M | 28.05M | 43.14M |
| Cash, Cash Equivalents and Short-Term Investments | 3.79M | 3.50M | 3.14M | 3.38M | 18.34M | 36.56M |
| Total Debt | 0.00 | 2.00K | 0.00 | 37.00K | 106.00K | 30.00K |
| Total Liabilities | 694.00K | 1.34M | 6.27M | 8.20M | 7.62M | 5.44M |
| Stockholders Equity | 7.16M | 6.84M | -2.17M | 607.00K | 20.43M | 37.69M |
Cash Flow | ||||||
| Free Cash Flow | -1.10M | -4.77M | -7.99M | -16.12M | -20.83M | -18.57M |
| Operating Cash Flow | -1.10M | -4.77M | -7.99M | -16.11M | -20.83M | -18.54M |
| Investing Cash Flow | -1.00K | 0.00 | 0.00 | -6.00K | -7.00K | -27.00K |
| Financing Cash Flow | 616.00K | 5.26M | 7.82M | 848.00K | 3.00M | 21.74M |
Bio Green Med Solution Technical Analysis
Negative
0.92
Price Trends
0.88
Positive
0.95
Negative
1.10
Negative
Market Momentum
>-0.01
Positive
45.33
Neutral
21.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of 0.92 is above the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.88, and below the 200-day MA of 1.10, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of 21.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.
Bio Green Med Solution Risk Analysis
Bio Green Med Solution disclosed 63 risk factors in its most recent earnings report. Bio Green Med Solution reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio Green Med Solution Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
48 Neutral | $68.32M | -0.46 | -234.45% | ― | ― | 36.23% | |
47 Neutral | $6.00M | -0.24 | -51.20% | ― | 18510.00% | 98.80% | |
47 Neutral | $21.24M | -0.36 | -113.35% | ― | ― | ― | |
44 Neutral | $5.69B | >-0.01 | -55.81% | ― | ― | 88.07% | |
44 Neutral | $4.29M | -0.08 | -144.27% | ― | ― | 93.91% |
* Industrials Sector Average
BGMS
Bio Green Med Solution
0.88
-7.12
-89.05%
BDRX
Biodexa Pharmaceuticals
1.26
-31.69
-96.18%
RNTX
Rein Therapeutics
0.79
-0.48
-37.56%
BJDX
Bluejay Diagnostics
0.94
-4.62
-83.11%
NEUP
Neuphoria Therapeutics
3.95
-3.23
-44.99%
Bio Green Med Solution Corporate Events
Business Operations and StrategyDividendsFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Bio Green Med Solution Reports Improved Q2 2026 Results
Positive
Aug 14, 2026
Bio Green Med Solution Inc., a Malaysia-headquartered Nasdaq-listed company, has transitioned from its former biopharmaceutical focus to a core business in fire safety protection and equipment distribution since acquiring Fitters Sdn. Bhd. in Sept...
Dividends
Bio Green Med Solution Declares Quarterly Preferred Stock Dividend
Positive
Jul 1, 2026
On July 1, 2026, Bio Green Med Solution, Inc. declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on August 1, 2026, to preferred stockholders of record as of the clos...
Executive/Board ChangesShareholder Meetings
Bio Green Med Solution Shareholders Approve Board and Auditors
Positive
Jun 22, 2026
At its 2026 Annual Meeting held on June 18, 2025, Bio Med Green Solution stockholders elected Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj as Class I directors for three-year terms expiring at the 2029 annual meeting, with each nominee ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Bio Green Med Solution Completes International Equity Private Placement
Positive
Jun 10, 2026
On June 10, 2025, Bio Green Med Solution, Inc. entered into a Securities Purchase Agreement with foreign accredited investors for the private placement of 1,103,338 shares of common stock at $0.72 per share, raising gross proceeds of $794,403 for ...
Business Operations and StrategyM&A Transactions
Bio Green Med Solution Announces Future NRG Acquisition Agreement
Positive
Jun 4, 2026
On June 4, 2026, Bio Green Med Solution, Inc. signed a Business Combination Agreement to acquire all shares of Malaysia-based Future NRG Sdn. Bhd. in an all-stock share exchange, with Future NRG becoming a wholly owned subsidiary and the combined ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.